A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
- T-cell Acute Lymphoblastic Leukemia
- Lymphoblastic Lymphoma
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- Allotera Therapeutics
- Enrolment target
- 125
- Started
- 31 January 2025
- Main results due
- 30 December 2026
- Study sites
- 18
- Registry updated
- 28 September 2026
Can you take part?
- Aged 6 months and over.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Key Inclusion Criteria: * Disease Criteria: Evidence of T-ALL or T-LBL, as defined by World Health Organization (WHO) classification, and either relapse/refractory or MRD positive * Age: Lower age limit of ≥ 6 months; adequate organ function * Eastern Cooperative Oncology Group (ECOG) 0 or 1/Karnofsky Performance Status 70 and above at Screening. Key Exclusion Criteria: * Prior treatment with any anti-CD7 therapy. * Patients with decompensated hemolytic anemia. * Presence of Grade 2 to 4 acute or extensive chronic GvHD requiring systemic immunosuppression. Grade 1 GvHD not requiring immunosuppression or Grade 2 skin GvHD if treated with topical therapy only are acceptable.
What this study is about
In the sponsor’s own words, from the registry.
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Study sites(18)
City of Hope
Duarte, California, United States
Recruiting
Children's Hospital Los Angeles
Los Angeles, California, United States
Recruiting
Colorado Blood Cancer Institute
Denver, Colorado, United States
Recruiting
Children's National Hospital
Washington D.C., District of Columbia, United States
Recruiting
H. Lee Moffitt Cancer Center and Research Institute Hospital
Tampa, Florida, United States
Recruiting
Children's Hospital of Atlanta
Atlanta, Georgia, United States
Recruiting
Washington University Saint Louis
St Louis, Missouri, United States
Recruiting
Memorial Sloan Kettering Cancer Center -- Pediatrics
New York, New York, United States
Recruiting
Oncology Hematology Care
Cincinnati, Ohio, United States
Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting
TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy
Nashville, Tennessee, United States
Recruiting
MD Anderson Cancer Center
Houston, Texas, United States
Recruiting
Sarah Cannon Transplant and Cellular Therapy Methodist Hospital
San Antonio, Texas, United States
Recruiting
Sarah Cannon, Virginia Oncology Associates
Norfolk, Virginia, United States
Recruiting
Seattle Children's Hospital
Seattle, Washington, United States
Recruiting
Peter Mac Callum Cancer Institute
Melbourne, Victoria, Australia
Recruiting
Royal Children's Melbourne
Melbourne, Victoria, Australia
Recruiting
Showing 18 of 18 sites. 18 of the 18 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT06514794. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me